“Although cisplatin-based chemotherapy has been a standard treatment approach for many patients with muscle-invasive bladder cancer, recurrence remains a significant challenge,” said Dr. Alfonso Gómez de Liaño, Hospital Universitario Insular de Gran Canaria, and KEYNOTE-B15 primary investigator.
The European Commission granted marketing authorization on October 21, 2026, for KEYTRUDA in combination with Padcev as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasive bladder cancer, regardless of cisplatin eligibility.
European Approval Expands Access
The decision by the European Commission expands the existing indication established through the EV-303 trial for cisplatin-ineligible patients, following a positive opinion in September 2026. Astellas Pharma Inc. announced that the expansion covers cisplatin-eligible adults based on results from the Phase 3 EV-304 trial.
“Based on results from the KEYNOTE-B15 trial, today’s approval is a meaningful advance for patients with muscle-invasive bladder cancer in the European Union, extending this chemotherapy-free perioperative treatment option to patients regardless of cisplatin eligibility,” Gómez de Liaño said in a news release on the approval.
Merck announced the European Commission approval from its headquarters in Rahway, New Jersey. The authorization also covers KEYTRUDA SC, known in the U.S. as KEYTRUDA QLEX.
“Building on the previous approval of KEYTRUDA plus Padcev in the European Union less than six months ago, we’re pleased to bring this important treatment option to a broader patient population as the first PD-1 inhibitor plus antibody-drug conjugate regimen approved for people with muscle-invasive bladder cancer regardless of cisplatin eligibility,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.
Clinical Trial Evidence and Survival Data
The EV-304 trial enrolled 808 patients with histologically confirmed muscle-invasive bladder cancer. Participants were randomized to receive either perioperative enfortumab vedotin plus pembrolizumab and radical cystectomy with pelvic lymph node dissection (n = 405) or standard neoadjuvant gemcitabine plus cisplatin (n = 403) followed by surgery.
Median event-free survival was not reached in the experimental arm, compared with 48.5 months in the gemcitabine and cisplatin arm. The combination reduced the risk of tumor recurrence, progression, or death by 47 percent, according to Astellas Global.
Additional findings from the study showed that the combination therapy demonstrated a statistically significant improvement in the pathologic complete response rate, reaching 55.8% compared to 32.5% for neoadjuvant chemotherapy. Furthermore, overall survival was significantly improved, with the regimen reducing the risk of death by 35% compared to the control arm.
“The EV-304 results demonstrate the potential to change the treatment trajectory for people with resectable muscle-invasive bladder cancer by bringing an effective perioperative approach into an earlier stage of disease,” said Moitreyee Chatterjee-Kishore, Ph.D., MBA, Executive Vice President and Head of Oncology Development, Astellas.
Grade 3 or higher adverse events of any cause occurred in 75.7 percent of patients treated with perioperative enfortumab vedotin plus pembrolizumab, compared with 67.2 percent of patients receiving neoadjuvant chemotherapy.
The findings were published in the New England Journal of Medicine in research co-authored by investigators from international institutions including the Mount Sinai Tisch Cancer Center and the Icahn School of Medicine at Mount Sinai in New York, the Hospital Universitario Virgen del Rocío in Seville, the Istituto Oncologico Veneto (IOV)–IRCCS in Padua, and the Catalan Institute of Oncology Badalona.
The European Commission, the European Union’s executive cabinet, traces its origins to the 1951 High Authority of the European Coal and Steel Community, which took office in Luxembourg City on 10 August 1952 under President Jean Monnet.
It became a single administration on 1 July 1967 through the Merger Treaty, combining the previously separate executives of the Coal and Steel Community, the European Economic Community, and Euratom. Today it comprises 27 commissioners — one per member state — and oversees roughly 32,000 European Civil Service staff organized into Directorates-General that function like national ministries.
Patients with muscle-invasive bladder cancer who are considering therapeutic choices should consult qualified medical professionals to discuss personalized treatment plans, potential side effects, and risk factors relevant to their specific health status.